Dr. Merit Cudkowicz (Massachusetts General Hospital) and Dr. Ammar Al-Chalabi (King's College London) discuss REFALS, a clinical trial for people with ALS. REFALS is a Phase 3 trial testing the effects of Oral Levosimendan (ODM-109) on breathing function. REFALS is ongoing and will enroll 450 participants across 104 sites in the U.S., Canada, EU and Australia.
